Dr. Reddy's Laboratories Ltd.

₹1,275.4

-0.6 (0%)

DRREDDY Share Price

Pharmaceuticals & Biotechnology

As on June 12, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,110 Cr

P/E Ratio18.81

Dividend Yield0.63 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,273.44	Bullish
10-DMA	1,274.06	Bullish
20-DMA	1,298.66	Bearish
50-DMA	1,277.3	Bearish
100-DMA	1,269.1	Bullish
200-DMA	1,263.91	Bullish

Historical Performance

1 Year

-6.4%

3 Years

36.4%

5 Years

16.9%

10 Years

108%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	3,26,439	2,80,111	2,46,697	2,15,452	1,90,475
Total Expenditure	2,40,968	2,00,780	1,83,207	1,77,778	1,51,776
Other Income	10,973	8,943	10,555	4,847	2,914
Operating Profit	96,444	88,274	74,045	42,521	41,613
Interest	2,829	1,711	1,428	958	970
Depreciation	17,037	14,700	12,502	11,652	12,288
Profit Before Tax	76,795	72,010	60,485	30,614	28,835
Consolidated Net Profit	56,551	55,779	45,073	21,825	19,516
Adjusted EPS	68	67	54	26	23

Compounded Sales Growth

10 Years:16.8

5 Years:13.3

3 Years:8.7

TTM:3.1

Compounded Profit Growth

10 Years:19.3

5 Years:22.8

3 Years:21

TTM:0.3

Stock Price CAGR

10 Years:7.5

5 Years:3.3

3 Years:9.9

TTM:-6.4

Return on Equity

10 Years:25

5 Years:23.5

3 Years:54.1

last year:67.8

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	834	834	833	832	832
Total Reserves	3,33,215	2,80,401	2,30,571	1,89,859	1,74,319
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	6,329	-368	-2,783	-5,083	-1,973
Other Current Liabilities	55,031	47,752	46,979	36,606	33,381
Short Term Borrowings	38,045	12,723	7,390	27,082	23,145
Total Liabilities	4,75,941	3,78,060	3,15,799	2,84,699	2,55,482
Capital Work in Progress	23,994	13,510	9,752	12,796	9,539
Long Term Loans & Advances	3,414	5,418	3,559	4,517	3,770
Currents Investments	33,306	44,050	44,495	20,229	13,785
Short Term Loans and Advances	20,043	32,763	9,267	8,441	7,227
Total Current Assets	2,50,181	2,48,053	2,04,254	1,77,879	1,45,352
Total Assets	4,75,941	3,78,060	3,15,799	2,84,699	2,55,482
Adjusted Book Value	401	337	278	1,146	1,053

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 18.81, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a moderate 3-year price CAGR of 9.9%, reflecting average market performance.
The stock carries a low beta of 0.6, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹96444 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹326439 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 946985.4

No. of Shares: 743 (Approx)

Performance:-5.3%

P/L: ₹-53014.6

NIFTY Performance: -4.4%

1 day Top Gainers